Saturday, August 23, 2014

A note on Methylnaltrexone

Subcutaneous methylnaltrexone (Relistor) rapidly induce laxation in patients with opioid-induced constipation. The major advantage is - the treatment usually does not affect central analgesia or precipitate opioid withdrawal. It cannot cross the blood–brain barrier, and so has antagonist effects throughout the body, counteracting effects such as itching and constipation, but without affecting opioid effects in the brain such as analgesia.


Jay Thomas, M.D., Ph.D., Sloan Karver, M.D., Gail Austin Cooney, M.D., Bruce H. Chamberlain, M.D., Charles Kevin Watt, D.O., Neal E. Slatkin, M.D., Nancy Stambler, M.S., Alton B. Kremer, M.D., Ph.D., and Robert J. Israel, M.D. - Methylnaltrexone for Opioid-Induced Constipation in Advanced Illness - N Engl J Med 2008; 358:2332-2343 - May 29, 2008

No comments:

Post a Comment